Intensity Therapeutics Inc. has entered into an agreement with Merck to evaluate the combination of Intensity’s lead product candidate INT230-6 and Keytruda (pembrolizumab), Merck’s anti-PD-1 therapy, in patients with advanced solid malignancies including pancreatic, bile duct, squamous cell, and non-MSI high colon cancers.
To access this subscriber-only content please log in or renew your subscription.
Looking for IP Login? Our IP Login system is now automatic. If your institution has a site license, please log in from on site or via your VPN to access this content.
Login Subscribe
Looking for IP Login? Our IP Login system is now automatic. If your institution has a site license, please log in from on site or via your VPN to access this content.
Login Subscribe